Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Growth failure and poor weight gain in children with inflammatory bowel disease

Jonathan E Teitelbaum, MD
Section Editors
Kathleen J Motil, MD, PhD
Melvin B Heyman, MD, MPH
Deputy Editor
Alison G Hoppin, MD


Growth failure is the most common extraintestinal manifestation of inflammatory bowel disease (IBD) in children and is particularly common among those with Crohn disease [1]. The causes of growth failure are complex and include the inflammatory process itself, as well as malnutrition and perhaps treatment with glucocorticoids.

The pathogenesis, evaluation, and treatment of growth failure or poor weight gain in children and adolescents with IBD will be reviewed here. The assessment and management of micronutrient deficiencies in these patients is discussed separately. (See "Nutrient deficiencies in inflammatory bowel disease".)


A combination of factors contributes to the pathogenesis of growth failure in children with IBD, including inflammation, malnutrition, hypogonadism, and glucocorticoid treatment.

Inflammation — There is increasing evidence that inflammation is an important mediator of growth failure in children with IBD [2,3]. This notion is supported by observed improvements in linear growth that occur after a variety of treatments that reduce inflammation in IBD, including surgical resection [4], infliximab [5-8], adalimumab [9,10], or exclusive enteral nutrition [11,12]. The improvement in growth is independent of weight gain or reductions in corticosteroid dose [1,7].

Inflammation probably inhibits linear growth through proinflammatory cytokines, including tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6). Although anti-TNF-alpha antibodies reduce disease activity [13], a direct association between TNF-alpha and growth failure remains elusive. IL-6 inhibits insulin-like growth factor 1 (IGF-1), which modulates the physiologic effects of growth hormone in a pattern suggestive of growth hormone resistance [2,14-17] and stimulating lipolysis [18]. Similarly, in pediatric Crohn disease patients who are CARD15 deficient, defects in innate immunity due to auto-antibodies to GM-CSF (granulocyte-macrophage colony stimulating factor) are associated with linear growth failure [19]. The authors speculate that the GM-CSF antibody in these genetically susceptible hosts contributes to increased intestinal permeability. The subsequent endotoxin exposure in turn causes growth hormone resistance as a mechanism for the resulting growth failure. Indeed in their murine model of ileitis they were able to demonstrate liver growth hormone resistance.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: May 2017. | This topic last updated: Jun 21, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Heuschkel R, Salvestrini C, Beattie RM, et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008; 14:839.
  2. Wong SC, Macrae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. J Pediatr Gastroenterol Nutr 2006; 43:144.
  3. Ley D, Duhamel A, Behal H, et al. Growth Pattern in Paediatric Crohn Disease Is Related to Inflammatory Status. J Pediatr Gastroenterol Nutr 2016; 63:637.
  4. Varille V, Cézard JP, de Lagausie P, et al. Resting energy expenditure before and after surgical resection of gut lesions in pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 1996; 23:13.
  5. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132:863.
  6. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007; 13:424.
  7. Malik S, Wong SC, Bishop J, et al. Improvement in growth of children with Crohn disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr 2011; 52:31.
  8. Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. Gastroenterology 2014; 146:383.
  9. Walters TD, Faubion WA, Griffiths AM, et al. Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohn's Disease. Inflamm Bowel Dis 2017; 23:967.
  10. Pichler J, Huber WD, Aufricht C, Bidmon-Fliegenschnee B. Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody. World J Gastroenterol 2015; 21:6613.
  11. Newby EA, Sawczenko A, Thomas AG, Wilson D. Interventions for growth failure in childhood Crohn's disease. Cochrane Database Syst Rev 2005; :CD003873.
  12. Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn's disease. J Pediatr Gastroenterol Nutr 1993; 17:75.
  13. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122:1592.
  14. Bresson JL, Schmitz J. Malnutrition in Crohn's disease: substrate deficiency or misuse? Horm Res 1992; 38 Suppl 1:76.
  15. Ballinger AB, Azooz O, El-Haj T, et al. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut 2000; 46:694.
  16. Sawczenko A, Azooz O, Paraszczuk J, et al. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. Proc Natl Acad Sci U S A 2005; 102:13260.
  17. De Benedetti F, Alonzi T, Moretta A, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997; 99:643.
  18. Yang Y, Ju D, Zhang M, Yang G. Interleukin-6 stimulates lipolysis in porcine adipocytes. Endocrine 2008; 33:261.
  19. D'Mello S, Trauernicht A, Ryan A, et al. Innate dysfunction promotes linear growth failure in pediatric Crohn's disease and growth hormone resistance in murine ileitis. Inflamm Bowel Dis 2012; 18:236.
  20. Hill KK, Hill DB, McClain MP, et al. Serum insulin-like growth factor-I concentrations in the recovery of patients with anorexia nervosa. J Am Coll Nutr 1993; 12:475.
  21. Azcue M, Rashid M, Griffiths A, Pencharz PB. Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone. Gut 1997; 41:203.
  22. Grill BB, Lange R, Markowitz R, et al. Delayed gastric emptying in children with Crohn's disease. J Clin Gastroenterol 1985; 7:216.
  23. Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32:913.
  24. Oliva MM, Lake AM. Nutritional considerations and management of the child with inflammatory bowel disease. Nutrition 1996; 12:151.
  25. Kirschner BS, DeFavaro MV, Jensen W. Lactose malabsorption in children and adolescents with inflammatory bowel disease. Gastroenterology 1981; 81:829.
  26. Pfefferkorn MD, Fitzgerald JF, Croffie JM, et al. Lactase deficiency: not more common in pediatric patients with inflammatory bowel disease than in patients with chronic abdominal pain. J Pediatr Gastroenterol Nutr 2002; 35:339.
  27. von Tirpitz C, Kohn C, Steinkamp M, et al. Lactose intolerance in active Crohn's disease: clinical value of duodenal lactase analysis. J Clin Gastroenterol 2002; 34:49.
  28. Mishkin B, Yalovsky M, Mishkin S. Increased prevalence of lactose malabsorption in Crohn's disease patients at low risk for lactose malabsorption based on ethnic origin. Am J Gastroenterol 1997; 92:1148.
  29. Hüppe D, Tromm A, Langhorst H, May B. [Lactose intolerance in chronic inflammatory bowel diseases]. Dtsch Med Wochenschr 1992; 117:1550.
  30. Perkal MF, Seashore JH. Nutrition and inflammatory bowel disease. Gastroenterol Clin North Am 1989; 18:567.
  31. Burbige EJ, Huang SH, Bayless TM. Clinical manifestations of Crohn's disease in children and adolescents. Pediatrics 1975; 55:866.
  32. Beeken WL. Absorptive defects in young people with regional enteritis. Pediatrics 1973; 52:69.
  33. Chan AT, Fleming CR, O'Fallon WM, Huizenga KA. Estimated versus measured basal energy requirements in patients with Crohn's disease. Gastroenterology 1986; 91:75.
  34. Zoli G, Katelaris PH, Garrow J, et al. Increased energy expenditure in growing adolescents with Crohn's disease. Dig Dis Sci 1996; 41:1754.
  35. Wiskin AE, Wootton SA, Cornelius VR, et al. No relation between disease activity measured by multiple methods and REE in childhood Crohn disease. J Pediatr Gastroenterol Nutr 2012; 54:271.
  36. Mingrone G, Capristo E, Greco AV, et al. Elevated diet-induced thermogenesis and lipid oxidation rate in Crohn disease. Am J Clin Nutr 1999; 69:325.
  37. Al-Jaouni R, Hébuterne X, Pouget I, Rampal P. Energy metabolism and substrate oxidation in patients with Crohn's disease. Nutrition 2000; 16:173.
  38. Steiner SJ, Pfefferkorn MD, Fitzgerald JF, Denne SC. Carbohydrate and lipid metabolism following infliximab therapy in pediatric Crohn's disease. Pediatr Res 2008; 64:673.
  39. Miura S, Yoshioka M, Tanaka S, et al. Faecal clearance of alpha 1-antitrypsin reflects disease activity and correlates with rapid turnover proteins in chronic inflammatory bowel disease. J Gastroenterol Hepatol 1991; 6:49.
  40. Griffiths AM, Drobnies A, Soldin SJ, Hamilton JR. Enteric protein loss measured by fecal alpha 1-antitrypsin clearance in the assessment of Crohn's disease activity: a study of children and adolescents. J Pediatr Gastroenterol Nutr 1986; 5:907.
  41. Stokes MA. Crohn's disease and nutrition. Br J Surg 1992; 79:391.
  42. Alemzadeh N, Rekers-Mombarg LT, Mearin ML, et al. Adult height in patients with early onset of Crohn's disease. Gut 2002; 51:26.
  43. Burnham JM, Shults J, Semeao E, et al. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone Miner Res 2004; 19:1961.
  44. Brain CE, Savage MO. Growth and puberty in chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 1994; 8:83.
  45. Azooz OG, Farthing MJ, Savage MO, Ballinger AB. Delayed puberty and response to testosterone in a rat model of colitis. Am J Physiol Regul Integr Comp Physiol 2001; 281:R1483.
  46. Hales DB, Diemer T, Hales KH. Role of cytokines in testicular function. Endocrine 1999; 10:201.
  47. Terranova PF, Rice VM. Review: cytokine involvement in ovarian processes. Am J Reprod Immunol 1997; 37:50.
  48. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003; 88:995.
  49. Vasseur F, Gower-Rousseau C, Vernier-Massouille G, et al. Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am J Gastroenterol 2010; 105:1893.
  50. Kleinman RE, Baldassano RN, Caplan A, et al. Nutrition support for pediatric patients with inflammatory bowel disease: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology And Nutrition. J Pediatr Gastroenterol Nutr 2004; 39:15.
  51. Motil KJ, Grand RJ, Davis-Kraft L, et al. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993; 105:681.
  52. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988; 95:1523.
  53. Booth IW. The nutritional consequences of gastrointestinal disease in adolescence. Acta Paediatr Scand Suppl 1991; 373:91.
  54. Gupta N, Lustig RH, Kohn MA, Vittinghoff E. Determination of bone age in pediatric patients with Crohn's disease should become part of routine care. Inflamm Bowel Dis 2013; 19:61.
  55. Gupta N, Lustig RH, Kohn MA, et al. Sex differences in statural growth impairment in Crohn's disease: role of IGF-1. Inflamm Bowel Dis 2011; 17:2318.
  56. Sawczenko A, Ballinger AB, Croft NM, et al. Adult height in patients with early onset of Crohn's disease. Gut 2003; 52:454.
  57. Ferguson A, Sedgwick DM. Juvenile onset inflammatory bowel disease: height and body mass index in adult life. BMJ 1994; 308:1259.
  58. Gupta N, Lustig RH, Kohn MA, Vittinghoff E. Menarche in pediatric patients with Crohn's disease. Dig Dis Sci 2012; 57:2975.
  59. Kugathasan S, Nebel J, Skelton JA, et al. Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts. J Pediatr 2007; 151:523.
  60. Rocha R, Santana GO, Almeida N, Lyra AC. Analysis of fat and muscle mass in patients with inflammatory bowel disease during remission and active phase. Br J Nutr 2009; 101:676.
  61. Motil KJ, Grand RJ, Maletskos CJ, Young VR. The effect of disease, drug, and diet on whole body protein metabolism in adolescents with Crohn disease and growth failure. J Pediatr 1982; 101:345.
  62. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Body composition in patients with inflammatory bowel disease: a population-based study. Am J Gastroenterol 2003; 98:1556.
  63. Motil KJ, Grand RJ, Matthews DE, et al. Whole body leucine metabolism in adolescents with Crohn's disease and growth failure during nutritional supplementation. Gastroenterology 1982; 82:1359.
  64. Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40:228.
  65. Laakso S, Valta H, Verkasalo M, et al. Compromised peak bone mass in patients with inflammatory bowel disease--a prospective study. J Pediatr 2014; 164:1436.
  66. Abraham BP, Prasad P, Malaty HM. Vitamin D deficiency and corticosteroid use are risk factors for low bone mineral density in inflammatory bowel disease patients. Dig Dis Sci 2014; 59:1878.
  67. American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:791.
  68. Hill RJ, Brookes DS, Davies PS. Bones in pediatric Crohn's disease: a review of fracture risk in children and adults. Inflamm Bowel Dis 2011; 17:1223.
  69. Pappa H, Thayu M, Sylvester F, et al. Skeletal health of children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 53:11.
  70. Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr 2012; 55:93.
  71. Gokhale R, Favus MJ, Karrison T, et al. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998; 114:902.
  72. Sylvester FA, Wyzga N, Hyams JS, et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:42.
  73. Dubner SE, Shults J, Baldassano RN, et al. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease. Gastroenterology 2009; 136:123.
  74. Hill GL, Blackett RL, Pickford IR, Bradley JA. A survey of protein nutrition in patients with inflammatory bowel disease--a rational basis for nutritional therapy. Br J Surg 1977; 64:894.
  75. Addolorato G, Capristo E, Stefanini GF, Gasbarrini G. Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand J Gastroenterol 1997; 32:1013.
  76. Tanner JM, Davies PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985; 107:317.
  77. Kirschner BS, Klich JR, Kalman SS, et al. Reversal of growth retardation in Crohn's disease with therapy emphasizing oral nutritional restitution. Gastroenterology 1981; 80:10.
  78. Imes S, Pinchbeck B, Thomson AB. Diet counselling improves the clinical course of patients with Crohn's disease. Digestion 1988; 39:7.
  79. Johnson T, Macdonald S, Hill SM, et al. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut 2006; 55:356.
  80. Hartman C, Berkowitz D, Weiss B, et al. Nutritional supplementation with polymeric diet enriched with transforming growth factor-beta 2 for children with Crohn's disease. Isr Med Assoc J 2008; 10:503.
  81. Han PD, Burke A, Baldassano RN, et al. Nutrition and inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28:423.
  82. Aiges H, Markowitz J, Rosa J, Daum F. Home nocturnal supplemental nasogastric feedings in growth-retarded adolescents with Crohn's disease. Gastroenterology 1989; 97:905.
  83. Belli DC, Seidman E, Bouthillier L, et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology 1988; 94:603.
  84. Wilschanski M, Sherman P, Pencharz P, et al. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut 1996; 38:543.
  85. Cameron FL, Altowati MA, Rogers P, et al. Disease Status and Pubertal Stage Predict Improved Growth in Antitumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2017; 64:47.
  86. McLain BI, Davidson PM, Stokes KB, Beasley SW. Growth after gut resection for Crohn's disease. Arch Dis Child 1990; 65:760.
  87. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119:895.
  88. Calenda KA, Schornagel IL, Sadeghi-Nejad A, Grand RJ. Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: a pilot study. Inflamm Bowel Dis 2005; 11:435.
  89. Heyman MB, Garnett EA, Wojcicki J, et al. Growth hormone treatment for growth failure in pediatric patients with Crohn's disease. J Pediatr 2008; 153:651.
  90. Wong SC, Hassan K, McGrogan P, et al. The effects of recombinant human growth hormone on linear growth in children with Crohn's disease and short stature. J Pediatr Endocrinol Metab 2007; 20:1315.
  91. Wong SC, Kumar P, Galloway PJ, et al. A preliminary trial of the effect of recombinant human growth hormone on short-term linear growth and glucose homeostasis in children with Crohn's disease. Clin Endocrinol (Oxf) 2011; 74:599.
  92. Denson LA, Kim MO, Bezold R, et al. A randomized controlled trial of growth hormone in active pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2010; 51:130.
  93. Vortia E, Kay M, Wyllie R. The role of growth hormone and insulin-like growth factor-1 in Crohn's disease: implications for therapeutic use of human growth hormone in pediatric patients. Curr Opin Pediatr 2011; 23:545.
  94. Ballinger AB, Savage MO, Sanderson IR. Delayed puberty associated with inflammatory bowel disease. Pediatr Res 2003; 53:205.